ArticleCancer management and research2026
Correlation Analysis Between Circulating Tumor DNA and Prognosis in Patients with Hepatocellular Carcinoma.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating tumor DNA in neoadjuvant therapy for solid tumors.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Circulating tumor DNA (ctDNA) is a noninvasive biomarker for tumor burden. Blood-based assays utilizing ctDNA copy number aberrations and fragment size show promise in hepatocellular carcinoma (HCC), but their prognostic value is unclear. This study evaluated the clinical relevance of a ctDNA-based score in predicting HCC prognosis. Patients and Methods: Clinical and ctDNA data from 93 HCC patients were analyzed. Patients were stratified by a predefined ctDNA score cutoff. Group comparisons used chi-square tests. Kaplan-Meier and multivariate Cox regression analyses assessed prognostic relevance. Results: Elevated ctDNA scores were associated with aggressive features: higher AFP and PIVKA-II levels, larger tumor size, macrovascular invasion, and advanced TNM stage (all P < 0.001). Patients with ctDNA scores > 0.61199 had significantly worse overall survival (OS). Univariate analysis identified 19 OS-associated variables, including inflammatory markers, biochemical indices, and tumor burden parameters. Multivariate analysis confirmed ctDNA score > 0.61199 (HR = 6.99, 95% CI 2.34-20.85, P < 0.001), AFP > 400 ng/mL (HR = 0.28, 95% CI 0.13-0.61, P = 0.001), ALB < 35.6 g/L (HR = 3.29, 95% CI 1.34-8.06, P = 0.009), and tumor number > 3 (HR = 3.85, 95% CI 1.58-9.40, P = 0.003) as independent prognostic determinants. Conclusion: Elevated ctDNA scores are strongly associated with adverse outcomes in HCC, highlighting their potential as a noninvasive prognostic biomarker. Integrating ctDNA assessment could improve risk stratification and treatment decisions, warranting validation in prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.